Literature DB >> 25786696

Haematological malignancies: at the forefront of immunotherapeutic innovation.

Pavan Bachireddy1, Ute E Burkhardt2, Mohini Rajasagi3, Catherine J Wu1.   

Abstract

The recent successes of cancer immunotherapies have stimulated interest in the potential widespread application of these approaches; haematological malignancies have provided both initial proofs of concept and an informative testing ground for various immune-based therapeutics. The immune-cell origin of many of the blood malignancies provides a unique opportunity both to understand the mechanisms of cancer immune responsiveness and immune evasion, and to exploit these mechanisms for therapeutic purposes.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25786696      PMCID： PMC4511812          DOI： 10.1038/nrc3907

Source DB:  PubMed          Journal:  Nat Rev Cancer        ISSN： 1474-175X            Impact factor:   60.716


  203 in total

Review 1.  Posttransplantation vaccination: concepts today and on the horizon.

Authors:  Katayoun Rezvani
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2011

Review 2.  Multiple myeloma.

Authors:  Antonio Palumbo; Kenneth Anderson
Journal:  N Engl J Med       Date:  2011-03-17       Impact factor: 91.245

3.  Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B-cell lymphoma.

Authors:  Michael R Green; Stefano Monti; Scott J Rodig; Przemyslaw Juszczynski; Treeve Currie; Evan O'Donnell; Bjoern Chapuy; Kunihiko Takeyama; Donna Neuberg; Todd R Golub; Jeffery L Kutok; Margaret A Shipp
Journal:  Blood       Date:  2010-07-13       Impact factor: 22.113

4.  Expression of tumor-associated antigens in acute myeloid leukemia: Implications for specific immunotherapeutic approaches.

Authors:  Jochen Greiner; Michael Schmitt; Li Li; Krzysztof Giannopoulos; Katrin Bosch; Anita Schmitt; Konstanze Dohner; Richard F Schlenk; Jonathan R Pollack; Hartmut Dohner; Lars Bullinger
Journal:  Blood       Date:  2006-08-24       Impact factor: 22.113

5.  CD28-mediated pro-survival signaling induces chemotherapeutic resistance in multiple myeloma.

Authors:  Megan E Murray; Catherine M Gavile; Jayakumar R Nair; Chandana Koorella; Louise M Carlson; Daniela Buac; Adam Utley; Marta Chesi; P Leif Bergsagel; Lawrence H Boise; Kelvin P Lee
Journal:  Blood       Date:  2014-04-29       Impact factor: 22.113

Review 6.  Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.

Authors:  Robert R Jenq; Marcel R M van den Brink
Journal:  Nat Rev Cancer       Date:  2010-02-19       Impact factor: 60.716

7.  Receptor for hyaluronan acid-mediated motility (RHAMM) is a new immunogenic leukemia-associated antigen in acute and chronic myeloid leukemia.

Authors:  Jochen Greiner; Mark Ringhoffer; Masanori Taniguchi; Anita Schmitt; Dieter Kirchner; Gertraud Krähn; Volker Heilmann; Jürgen Gschwend; Lothar Bergmann; Hartmut Döhner; Michael Schmitt
Journal:  Exp Hematol       Date:  2002-09       Impact factor: 3.084

8.  Biologic activity of irradiated, autologous, GM-CSF-secreting leukemia cell vaccines early after allogeneic stem cell transplantation.

Authors:  Vincent T Ho; Matthew Vanneman; Haesook Kim; Tetsuro Sasada; Yoon Joong Kang; Mildred Pasek; Corey Cutler; John Koreth; Edwin Alyea; Stefanie Sarantopoulos; Joseph H Antin; Jerome Ritz; Christine Canning; Jeffery Kutok; Martin C Mihm; Glenn Dranoff; Robert Soiffer
Journal:  Proc Natl Acad Sci U S A       Date:  2009-08-26       Impact factor: 11.205

9.  Wilms tumor gene peptide-based immunotherapy for patients with overt leukemia from myelodysplastic syndrome (MDS) or MDS with myelofibrosis.

Authors:  Yoshihiro Oka; Akihiro Tsuboi; Masaki Murakami; Manabu Hirai; Nobuhiko Tominaga; Hiroko Nakajima; Olga A Elisseeva; Tomoki Masuda; Akiko Nakano; Manabu Kawakami; Yusuke Oji; Kazuhiro Ikegame; Naoki Hosen; Keiko Udaka; Masaki Yasukawa; Hiroyasu Ogawa; Ichiro Kawase; Haruo Sugiyama
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

10.  Nivolumab plus ipilimumab in advanced melanoma.

Authors:  Jedd D Wolchok; Harriet Kluger; Margaret K Callahan; Michael A Postow; Naiyer A Rizvi; Alexander M Lesokhin; Neil H Segal; Charlotte E Ariyan; Ruth-Ann Gordon; Kathleen Reed; Matthew M Burke; Anne Caldwell; Stephanie A Kronenberg; Blessing U Agunwamba; Xiaoling Zhang; Israel Lowy; Hector David Inzunza; William Feely; Christine E Horak; Quan Hong; Alan J Korman; Jon M Wigginton; Ashok Gupta; Mario Sznol
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245
View more
  31 in total

Review 1.  Leukaemia 'firsts' in cancer research and treatment.

Authors:  Mel Greaves
Journal:  Nat Rev Cancer       Date:  2016-03       Impact factor: 60.716

Review 2.  Personal tumor antigens in blood malignancies: genomics-directed identification and targeting.

Authors:  Livius Penter; Catherine J Wu
Journal:  J Clin Invest       Date:  2020-04-01       Impact factor: 14.808

Review 3.  Genomic and epigenomic heterogeneity in chronic lymphocytic leukemia.

Authors:  Romain Guièze; Catherine J Wu
Journal:  Blood       Date:  2015-06-11       Impact factor: 22.113

Review 4.  Recent advances in T-cell immunotherapy for haematological malignancies.

Authors:  Rayne H Rouce; Sandhya Sharma; Mai Huynh; Helen E Heslop
Journal:  Br J Haematol       Date:  2016-11-29       Impact factor: 6.998

Review 5.  Towards personalized, tumour-specific, therapeutic vaccines for cancer.

Authors:  Zhuting Hu; Patrick A Ott; Catherine J Wu
Journal:  Nat Rev Immunol       Date:  2017-12-11       Impact factor: 53.106

Review 6.  ADARs, RNA editing and more in hematological malignancies.

Authors:  Phaik Ju Teoh; Mun Yee Koh; Wee Joo Chng
Journal:  Leukemia       Date:  2020-11-02       Impact factor: 11.528

7.  Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients.

Authors:  V Gopalakrishnan; C N Spencer; L Nezi; A Reuben; M C Andrews; T V Karpinets; P A Prieto; D Vicente; K Hoffman; S C Wei; A P Cogdill; L Zhao; C W Hudgens; D S Hutchinson; T Manzo; M Petaccia de Macedo; T Cotechini; T Kumar; W S Chen; S M Reddy; R Szczepaniak Sloane; J Galloway-Pena; H Jiang; P L Chen; E J Shpall; K Rezvani; A M Alousi; R F Chemaly; S Shelburne; L M Vence; P C Okhuysen; V B Jensen; A G Swennes; F McAllister; E Marcelo Riquelme Sanchez; Y Zhang; E Le Chatelier; L Zitvogel; N Pons; J L Austin-Breneman; L E Haydu; E M Burton; J M Gardner; E Sirmans; J Hu; A J Lazar; T Tsujikawa; A Diab; H Tawbi; I C Glitza; W J Hwu; S P Patel; S E Woodman; R N Amaria; M A Davies; J E Gershenwald; P Hwu; J E Lee; J Zhang; L M Coussens; Z A Cooper; P A Futreal; C R Daniel; N J Ajami; J F Petrosino; M T Tetzlaff; P Sharma; J P Allison; R R Jenq; J A Wargo
Journal:  Science       Date:  2017-11-02       Impact factor: 47.728

Review 8.  Antigen Discovery and Therapeutic Targeting in Hematologic Malignancies.

Authors:  David A Braun; Catherine J Wu
Journal:  Cancer J       Date:  2017 Mar/Apr       Impact factor: 3.360

Review 9.  Myeloid-derived suppressor cells in B cell malignancies.

Authors:  Yaghoub Yazdani; Mousa Mohammadnia-Afrouzi; Mehdi Yousefi; Enayat Anvari; Ghasem Ghalamfarsa; Hadi Hasannia; Sanam Sadreddini; Farhad Jadidi-Niaragh
Journal:  Tumour Biol       Date:  2015-09-02

10.  Synthesis and biological evaluation of santacruzamate A analogues for anti-proliferative and immunomodulatory activity.

Authors:  Samantha M Gromek; James A deMayo; Andrew T Maxwell; Ashley M West; Christopher M Pavlik; Ziyan Zhao; Jin Li; Andrew J Wiemer; Adam Zweifach; Marcy J Balunas
Journal:  Bioorg Med Chem       Date:  2016-08-24       Impact factor: 3.641
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.